Literature DB >> 11328819

Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells.

H J List1, K J Lauritsen, R Reiter, C Powers, A Wellstein, A T Riegel.   

Abstract

Human breast tumorigenesis is promoted by the estrogen receptor pathway, and nuclear receptor coactivators are thought to participate in this process. Here we studied whether one of these coactivators, AIB1 (amplified in breast cancer 1), was rate-limiting for hormone-dependent growth of human MCF-7 breast cancer cells. We developed MCF-7 breast cancer cell lines in which the expression of AIB1 can be modulated by regulatable ribozymes directed against AIB1 mRNA. We found that depletion of endogenous AIB1 levels reduced steroid hormone signaling via the estrogen receptor alpha or progesterone receptor beta on transiently transfected reporter templates. Down-regulation of AIB1 levels in MCF-7 cells did not affect estrogen-stimulated cell cycle progression but reduced estrogen-mediated inhibition of apoptosis and cell growth. Finally, upon reduction of endogenous AIB1 expression, estrogen-dependent colony formation in soft agar and tumor growth of MCF-7 cells in nude mice was decreased. From these findings we conclude that, despite the presence of different estrogen receptor coactivators in breast cancer cells, AIB1 exerts a rate-limiting role for hormone-dependent human breast tumor growth.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328819     DOI: 10.1074/jbc.M102397200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Xiaodong Sun; Peng Guo; Qunna Li; Masakiyo Sasahara; Yoko Ishii; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

2.  Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1.

Authors:  Tyler Lahusen; Mark Fereshteh; Annabell Oh; Anton Wellstein; Anna T Riegel
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

3.  Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA.

Authors:  Anwar Hossain; Macus T Kuo; Grady F Saunders
Journal:  Mol Cell Biol       Date:  2006-08-28       Impact factor: 4.272

4.  Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy.

Authors:  Neeraj K Saxena; Dipali Sharma
Journal:  Mol Cell Pharmacol       Date:  2010

5.  Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.

Authors:  Sudipan Karmakar; Estrella A Foster; Julia K Blackmore; Carolyn L Smith
Journal:  Endocr Relat Cancer       Date:  2010-12-21       Impact factor: 5.678

6.  Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.

Authors:  I E Obiorah; V C Jordan
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

7.  The role of AIB1 in breast cancer.

Authors:  Alan K Chang; Huijian Wu
Journal:  Oncol Lett       Date:  2012-07-16       Impact factor: 2.967

8.  Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter.

Authors:  Stephanie J Ellison-Zelski; Natalia M Solodin; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

9.  Generation and validation of a mouse line with a floxed SRC-3/AIB1 allele for conditional knockout.

Authors:  Zhaoliang Liu; Lan Liao; Suoling Zhou; Jianming Xu
Journal:  Int J Biol Sci       Date:  2008-07-23       Impact factor: 6.580

10.  Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.

Authors:  Annabell S Oh; John T Lahusen; Christopher D Chien; Mark P Fereshteh; Xiaolong Zhang; Sivanesan Dakshanamurthy; Jianming Xu; Benjamin L Kagan; Anton Wellstein; Anna T Riegel
Journal:  Mol Cell Biol       Date:  2008-09-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.